Bridging the gap: The critical role of laboratory developed tests in clinical toxicology [0.03%]
bridging the gap：临床毒理学中实验室开发试验的关键作用
Jaime H Noguez,Christopher D Koch
Jaime H Noguez
•Toxicology testing provides valuable information for patient management.•Current in vitro diagnostics (IVDs) are unable to meet all clinical needs.•Lab-developed tests (LDTs) in toxicology can be used to close clinical care gaps.•LDTs ...
Small molecule biomarker discovery: Proposed workflow for LC-MS-based clinical research projects [0.03%]
基于LC-MS的临床研究项目的小微企业生物标志物发现：建议的工作流程
S Rischke,L Hahnefeld,B Burla et al.
S Rischke et al.
Mass spectrometry focusing on small endogenous molecules has become an integral part of biomarker discovery in the pursuit of an in-depth understanding of the pathophysiology of various diseases, ultimately enabling the application of perso...
Impact of VALID Act implementation on mass spectrometry-based clinical proteomic laboratory developed tests [0.03%]
《VALID法案的实施对基于质谱的临床蛋白质组实验室开发试验的影响》
Yanchun Lin,Stefani N Thomas
Yanchun Lin
Mass spectrometry (MS)-based clinical proteomic Laboratory Developed Tests (LDTs) for the measurement of protein biomarkers related to endocrinology, cardiovascular disease, cancer, and Alzheimer's disease are gaining traction in clinical l...
How the VALID Act could affect patient access to laboratory developed testing for therapeutic drug monitoring [0.03%]
《合法验证法案》如何影响患者获得治疗药物监测实验室开发检验的途径
Alec Saitman
Alec Saitman
•LDTs are important to lab medicine as they allow flexibility for laboratories to provide testing that patients need.•Many TDMs are LCMS-based and are considered LDTs.•Some TDMs currently have little to no options for obtaining FDA clear...
Impact of the loss of Laboratory Developed Mass Spectrometry testing at a major academic medical center [0.03%]
大型学术医学中心实验室开发的质谱检测丢失的影响
K Aaron Geno,Mark A Cervinski
K Aaron Geno
Background: Our laboratory historically performed immunosuppressant and definitive opioid testing in-house as laboratory developed (LDT) mass spectrometry-based tests. However, staffing constraints and supply chain challe...
Molecular diagnostics and the laboratory developed test: A tale of success and the potential impacts of increased regulation [0.03%]
分子诊断和实验室开发检测：成功案例与增加监管潜在影响的故事
Gregory J Tsongalis
Gregory J Tsongalis
Discovery of a biomarker for β-Thalassemia by HPLC-MS and improvement from Proton Transfer Reaction - Parallel Ion Parking [0.03%]
液相色谱质谱发现β-地中海贫血生物标志物并采用 proton transfer reaction 平行离子停车技术改善检测效果
Yuan Lin,Archana M Agarwal,Lissa C Anderson et al.
Yuan Lin et al.
β-thalassemia is a quantitative hemoglobin (Hb) disorder resulting in reduced production of Hb A and increased levels of Hb A2. Diagnosis of β-thalassemia can be problematic when combined with other structural Hb variants, so that the sep...
Ashley R Rackow,Claire E Knezevic
Ashley R Rackow
Pre-analytical conditions influencing analysis of folate in dried plasma microsamples [0.03%]
干血浆微样本叶酸分析的前处理条件的影响因素研究
Christopher M Shuford,Evan W McConnell,Stacy Dee et al.
Christopher M Shuford et al.
Introduction: Determination of folate insufficiency is of considerable interest given its importance in fetal development and red blood cell formation; however, access to blood tests may be limited due to the requirement ...